Glucose tolerance and markers of myocardial injury after an acute coronary syndrome: predictive role of the 1-h plus 2-h plasma glucose at the oral glucose tolerance test

Table 1 In-hospital outcome measures: cardiac biomarkers and cardiac function parameters in the four patient groups

	All Patients n = 88	Group A n = 12	Group B n = 33	Group C n = 8	Group D n = 35	P-value
Hospitalization duration (daya)	6.0 (5.0–7.0)	5.0 (4.2–5.7)	6.0 (5.0–7.0)	6.5 (5.0–7.7)	7.0 (6.0–8.0)	0.02*
LVEF admission (%)	51 (44–58)	55 (53–59)	51 (44–58)	50 (40–58)	51 (42–55)	0.08
NT-proBNP (ng/L)	689 (277–1348)	370 (124–770)	671 (311–1301)	220 (122–700)	1123 (551–2686)	0.001**
BNP (pg/mL)	99 (38–197)	45 (16–172)	61 (33–133)	123 (38–172)	148 (78–378)	0.12
Admission hs-Troponin T (ng/L)	292 (46–1131)	42 (21–375)	166 (57–472)	29 (10–235)	911 (245–2976)	0.001***
Discharge hs-Troponin T (ng/L)	251 (97–658)	284 (63–661)	155 (35–259)	18 (49 -1120)	399 (202–850)	0.056
Peak hs-Troponin T (ng/L)	1331 (355–3743)	522 (175–1495)	654 (232–1694)	1853 (87–5063)	2113 (1327–7483)	0.003****

Group A: patients with normal glucose tolerance and 1 h-PG < 155 mg/dL; Group B: patient with normal glucose tolerance and 1 h-PG ≥ 155 mg/dL; Group C: patients with IGT characterized by 1 h-PG < 155 mg/dL; Group D: patients with IGT including 1 h-PG ≥ 155 mg/dL
Two-tailed P-values < 0.05 were considered as statistically significant. Continuos variables were expressed with median and interquartiles intervals
hs-Troponin T high-sensitivity Troponin T, LVEF left ventricular ejection fraction, OGTT-PG oral glucose tolerance test plasma glucose, PG plasma glucose
^* = Statistically significant multiple comparisons: A vs D: P = 0.005
^** = Statistically significant multiple comparison: A vs D: P = 0.008, C vs D: P = 0.015
^*** = Statistically significant multiple comparison: A vs D: P = 0.013, B vs D: P = 0.023, C vs D P = 0.005
^**** = Statistically significant multiple comparisons: A vs D: P = 0.024, D vs B, P = 0

ISSN: 1475-2840